Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03662659 · ClinicalTrials.gov registry record · Phase 2
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
A Phase 2 study of Gastric Cancer and Esophagogastric Junction, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
- 20
- Study locations
NCT03662659: Completed Phase 2 study of Gastric Cancer and Esophagogastric Junction, sponsored by Bristol-Myers Squibb.
NCT03662659 is a Phase 2 study of Gastric Cancer and Esophagogastric Junction that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 274 participants, below the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03662659, a Phase 2 study of Gastric Cancer and Esophagogastric Junction, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic gastric or GEJ cancer.
Primary Outcome
The number of LAG-3 Positive (\>=1%) participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) divided by the number of randomized LAG-3 positive (\>=1%) participants in each arm; recorded between randomization date and the date of objectively documented progression \[per RECISIT 1.1\], death due to any cause, or date of subsequent anticancer therapy, whichever occurs first. CR= Disappearance of all target lesions PR= At least a 30% decrease in
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- DRUG FOLFOX
- DRUG XELOX
- DRUG SOX
- BIOLOGICAL BMS-986213
Study Locations (20)
California
- Local Institution - 0049 - Clovis
- Local Institution - 0064 - Duarte
- Scripps Clinic - La Jolla
- Local Institution - 0040 - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Local Institution - 0041 - Orange
- Local Institution - 0077 - Santa Monica
Colorado
- Local Institution - 0056 - Aurora
Connecticut
- Local Institution - 0062 - New Haven
New Jersey
- Local Institution - 0050 - Hackensack
Texas
- Local Institution - 0054 - Dallas
Virginia
- Virginia Cancer Institute - Richmond
Washington
- Local Institution - 0052 - Seattle
Buenos Aires
- Local Institution - 0010 - Ciudad Autónoma de Buenos Aires
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2018-10-16 |
| Est. Completion | 2024-01-18 |
| Phase | Phase 2 |
What the finished NCT03662659 record still lists
NCT03662659 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, below the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target (14% lower).
The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.
NCT03662659 names 20 study sites across 14 states, led by California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03662659 about?
NCT03662659 is a clinical study titled "An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers". The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic gastric or GEJ cancer.
What is the current status of trial NCT03662659?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2018-10-16. Estimated completion is 2024-01-18.
What conditions does trial NCT03662659 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophagogastric Junction, Cancer of the Stomach.
What interventions are being tested in trial NCT03662659?
The interventions under investigation include: Nivolumab (BIOLOGICAL), FOLFOX (DRUG), XELOX (DRUG), SOX (DRUG), BMS-986213 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03662659?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03662659 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03662659's enrollment target sits among peer trials
274 43rd of 153 higher than 111 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
- NCT05952583 · 274 participants
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI